China Medical System (HKG:0867, SGX:8A8) obtained approval from China's National Medical Products Administration for the clinical trial of the self-developed complement factor B inhibitor CMS-D017 capsules, according to a Wednesday filing with the Singapore Exchange.
Under the approval, the pharmaceutical company can now conduct trials to evaluate the drug's safety and efficacy for treating age-related macular degeneration.
Aussie Broadband's (ASX:ABB) ability to deliver its fiscal year 2028 ambitions will face limited impact from the threat of satellite internet disruption, Jarden said in a Tuesday report.Starlink could emerge as a structural threat, amid SpaceX's stated ambition to move upmarket into suburban and urban premises. However, Starlink's share gains to date have not come at the expense of NBN connections. Starlink has lifted total household internet penetration, while fixed-line NBN connections have remained stable in absolute terms.Aussie Broadband's group cost growth, excluding acquisitions, will run below the consumer price index, allowing the firm to grow earnings organically ahead of market expectations despite the residential slowdown. It will compound underlying earnings before interest, taxes, depreciation, and amortization at around 21%, from fiscal year 2025 to fiscal year 2028.The investment firm upgraded its rating on Aussie Broadband to overweight from neutral and retained its AU$5.50 per share price target.
The Korea Exchange activated a five-minute buy-side sidecar on the country's primary and secondary stock markets on Wednesday morning after investors rushed to buy semiconductor stocks amid an upbeat AI sector outlook despite tensions in the Middle East.The Korea Exchange announced the order at 9:06 am after the KOSPI200 Futures added 71.50 points, or 6.5%, to trade at 1,170.60, and at 9:17 am after the KOSDAQ150 Futures index added 83 points, or 6.1%, to trade at 1,439.50.A buy-side sidecar is activated when the KOSPI200 Futures index and the KOSDAQ150 Futures index rise 5% or more for at least one minute.
China Southern Airlines (HKG:1055, SHA:600029) expects an attributable net loss of 3.47 billion yuan to 3.97 billion yuan for the first half, widening from 1.53 billion yuan a year earlier, according to a Tuesday filing with the Hong Kong bourse.The company attributed the expected loss to sharply higher aviation fuel costs amid geopolitical tensions, despite growth in passenger traffic and revenue during the first half.Hong Kong-listed shares of the airline were down nearly 2% in Wednesday morning trade.